Similar articles

• Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.

  Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B. Armstrong K, et al. J Clin Oncol. 2004 Mar 15;22(6):1045-54. doi: 10.1200/JCO.2004.06.090. Epub 2004 Feb 23. J Clin Oncol. 2004. PMID: 14981106
• Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.

  Biglia N, Mariani L, Ponzone R, Sismondi P. Biglia N, et al. Maturitas. 2008 Jun 20;60(2):71-7. doi: 10.1016/j.maturitas.2008.03.004. Epub 2008 May 9. Maturitas. 2008. PMID: 18472232 No abstract available.
• Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.

  Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Casey MJ, et al. Gynecol Oncol. 2005 May;97(2):457-67. doi: 10.1016/j.ygyno.2005.01.039. Gynecol Oncol. 2005. PMID: 15863145
• Prophylactic oophorectomy in women at increased cancer risk.

  Domchek SM, Rebbeck TR. Domchek SM, et al. Curr Opin Obstet Gynecol. 2007 Feb;19(1):27-30. doi: 10.1097/GCO.0b013e32801195da. Curr Opin Obstet Gynecol. 2007. PMID: 17218848 Review.
• Hereditary ovarian cancer--assessing risk and prevention strategies.

  Pavelka JC, Li AJ, Karlan BY. Pavelka JC, et al. Obstet Gynecol Clin North Am. 2007 Dec;34(4):651-65, vii-viii. doi: 10.1016/j.ogc.2007.09.005. Obstet Gynecol Clin North Am. 2007. PMID: 18061862 Review.